Crossmark

Evaluation of the robustness of randomized controlled trials for the treatment modalities of esophageal cancer using the fragility index – a systematic review

Crossref DOI link: https://doi.org/10.1007/s00464-024-11343-3

Published Online: 2024-10-23

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kahana, Noam

Boaz, Elad

Horesh, Nir

Emile, Sameh Hany

Dourado, Justin

Aeschbacher, Pauline

Rogers, Pete

Gefen, Rachel

Lo Menzo, Emanuele

Rosenthal, Raul J. https://orcid.org/0000-0002-7663-2464
License Information

Text and Data Mining valid from 2024-10-23

Version of Record valid from 2024-10-23
More Information

Article History

Received: 16 March 2024

Accepted: 6 October 2024

First Online: 23 October 2024

Declarations

:

: Drs. Noam Kahana, Elad Boaz, Nir Horesh, Sameh Hany Emile, Justin Dourado, Pauline Aeschbacher, Pete Rogers, Rachel Gefen, and Emanuele Lo Menzo have no conflicts of interest or financial ties to disclose. Dr. Raul Rosenthal receives speaker honoraria from Medtronics, serves on the Advisory Board and receives honoraria from Diagnostic Green; receives educational grants from Olympus, Stryker, Medtronic, Diagnostic Green, Arthrex, and Storz; is a shareholder in Medicad Simulation/Dendrite Imaging, and serves on the Advisory Board and as Interim CEO for Dendrite Imaging.

Document is current

Any future updates will be listed below